Phase I/II Open-label, Multiple-dose, Dose Escalation Study to Evaluate the Safety and Effectiveness of IMO-8400 in Patients With Relapsed or Refractory DLBCL and Presence of the MyD88L265P Mutation

Trial Profile

Phase I/II Open-label, Multiple-dose, Dose Escalation Study to Evaluate the Safety and Effectiveness of IMO-8400 in Patients With Relapsed or Refractory DLBCL and Presence of the MyD88L265P Mutation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs IMO 8400 (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2017 Status changed from suspended to completed.
    • 28 Oct 2016 According to an Idera Pharmaceuticals media release, this trial has been suspended due to prioritization of the clinical development plans for IMO-2125, assessment showing level of clinical activity seen in the WM trial does not support monotherapy, the very slow enrollment rate in DLBCL and the Companys commercial assessment of IMO-8400.
    • 28 Oct 2016 Status changed from active, no longer recruiting to suspended, as reported by an Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top